The first was an open-label randomized trial evaluating oral torsemide (n=113) versus furosemide (n=121) in those with heart failure with reduced ejection fraction and on angiotensin converting enzyme inhibitors showed a statistically significant difference in heart failure readmissions (32% versus 17%, P < 0.01). This evidence concerns the gene ACE and heart failure.